Another important aspect to note is that steroids used in low doses and given at the beginning of RA have demonstrably less adverse effects than previously thought. Its use provides relief to patients with a good safety profile, in addition to decreasing radiological progression several years after being suspended.
Despite recent advances, the causes of RA remain unknown and there is still a group of patients refractory to biological agents Flekosteel. More clinical and basic research is urgently needed to understand the etiopathogenesis of this disease and develop new therapeutic options.
No comments:
Post a Comment